Michael Kolodziej, MD: The question about what determines on pathway/off pathway or, more globally, pathway content, it’s been a challenge, I think, for people who work in this area for a very, very long time. And when I was in oncology and part of the pathways group, we had very long, very complicated meetings that went through everything with a fine-tooth comb. When I went to the health plan, I told them I was not going to manage content because that would take up every single minute of my time. So, we chose to go with a vendor, and we delegated content management to that vendor. That vendor, in turn, has a committee of academic and community physicians that contribute to the synthesis of the content. I do not get a vote on those committee meetings. I don’t even attend those committee meetings. We do mandate that the content of the pathways harmonize with our coverage policy, but that’s not hard. The pathway vendor that we use actually licenses NCCN content now because their coverage policy reflects NCCN content. There’s no conflict.
I think different pathways companies, pathways developers, they follow different recipes for determining what the appropriate level of evidence is. But I always say, “You know, if it really works, you’ve got nothing to worry about. It’s going to be on pathway. That’s the way it is.” There is no pathway in the universe, none, that does not have Herceptin first-line, adjuvant, you name it. There’s no pathways company in the world that does not have the PD-1 drugs second-line, irrespective of histology, in non—small cell carcinoma. There just are no pathways that don’t allow those treatments. Why? Because they’re so clearly better than anything else we’ve got. So, people get, I think, a little bent out of shape around the edges, where they ask, “Is that endpoint adequate to make it on pathway versus off pathway?” or “How much are you considering the cost?”, and I have just decided to divorce myself from those discussions because I cannot win.
The consequences of not being on pathway actually vary depending on the payer, and I’ll just tell you how we approach it. The pathways actually have no influence on coverage policy. It’s a really important distinction. Because people got this impression, that is totally wrong, that if you’re off pathway, the treatment is not going to get paid for; the treatment will be paid for if it’s consistent with our coverage policy, and those are publicly available. And if you don’t look it up, then if it’s NCCN 2B or better, you’re on pretty good ground. Okay, so that’s number one. Number two is, because we have chosen to go with aggregate-level reporting in levels of performance, there is a quality performance pool if you achieve a certain threshold. And, in fact, that threshold is graded, so if you are better than 65% compliant, you get something. If you’re better than 75% compliant, you get something extra. And if you’re better than 80% compliant, you get something extra yet. So, there’s a gradation. We do not reward people for being greater than 80% compliant. We do consider the entire book of business when we measure performance compliance.
So, that’s how we do it. I know other people do it other ways. It’s a fair way. It does allow you to, for example, not be punished for a case mix, a distribution of patients that might be particularly challenging to treat on pathway. It allows you to spread that risk over your entire patient population.
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Kaiser Permanente was hit by a data breach in mid-April, impacting 13.4 million health plan members; GlaxoSmithKline (GSK) sued Pfizer and BioNTech for allegedly infringing on its messenger RNA technology patents in the companies’ COVID-19 vaccines; the CDC announced the first-known HIV cases transmitted via cosmetic injections.
Read More